Effect of Inhaled Salbutamol on outcome of Transient Tachypnea of Newborn (TTN) in Neonatal Care Unit at AIMS Muzaffarabad
DOI:
https://doi.org/10.51985/Keywords:
B2-Agonist, Neonatal Respiratory Distress, Salbutamol, Transient Tachypnea of the NewbornAbstract
Objective: To compare the outcome of inhaled salbutamol versus placebo, in addition to standard treatment, among neonates with TTN.
Study Design and Setting: A cross-sectional study was conducted in the Neonatal Unit, Department of Pediatrics Medicine, Abbas Institute of Medical Sciences, Muzaffarabad, over six months (14-Feb-2025 to 13-August-2025). Methodology: The study included a total of 80 neonates who fulfilled the inclusion criteria. Neonates were divided into two groups in accordance with the treatment given to them as part of standard clinical treatment: inhaled salbutamol or nebulized normal saline. Descriptive analysis was performed using SPSS version 25. Quantitative variables were given as mean ± standard deviation, while qualitative variables were reported as frequencies and percentages. An independent sample t-test was conducted to compare outcomes between the two groups. Statistical significance was defined as p=0.05. Results: The duration of oxygen therapy was significantly shorter in the salbutamol group (32.75 ± 2.12 hours) compared to the control group (78.20 ± 2.77 hours; p = 0.001). Similarly, the mean length of hospital stay was significantly reduced in the salbutamol group (3.05 ± 1.15 days) compared to the control group (5.78 ± 1.00 days; p = 0.001). Conclusion: Inhaled salbutamol, in addition to standard treatment significantly reduced the length of oxygen withdrawal and length of hospital stay in neonates with TTN. It might therefore represent effective adjuvant therapy to enhance the outcome and lessen the burden on hospitals of infants with the condition
References
1. Iramain R, Castro-Rodriguez JA, Jara A, Cardozo L, Bogado
N, Morinigo R, et al. Salbutamol and ipratropium by inhaler
is superior to nebulizer in children with severe acute asthma
exacerbation: Randomized clinical trial. Pediatr Pulmonol.
2019;54(4):372-7. DOI: https://doi.org/10.1002/ppul.24244.
2. Selewski DT, Gist KM, Nathan AT, Goldstein SL, Boohaker
LJ, Akcan-Arikan A, et al. The impact of fluid balance on
outcomes in premature neonates: a report from the AWAKEN
study group. Pediatr Res. 2020;87(3):550-7. DOI:
https://www.nature.com/articles/s41390-019-0579-1.
3. Daley SF, Nassar GN, Makker K. Transient tachypnea of the
newborn. InStatPearls [Internet] 2025. DOI: https://www.ncbi.
nlm.nih.gov/books/NBK537354/.
4. Moresco L, Bruschettini M, Macchi M, Calevo MG.
Salbutamol for transient tachypnea of the newborn. Cochrane
Database of Systematic Reviews. 2021;2(2):150-5. DOI:
https://doi.org/10.1002/14651858.CD011878.pub3.
5. Sardar S, Pal S, Mishra R. A randomized controlled trial of
restricted versus standard fluid management in late preterm
and term infants with transient tachypnea of the newborn. J
Neonatal-Perinatal Med. 2020;13(4):477-87. DOI:
https://doi.org/10.3233/NPM-190400.
6. Senaldi L, Blatt L, Han JY, Gozum G, Venturini SL, Hauft S,
et al. A quality improvement initiative to reduce antibiotic
use in transient tachypnea of the newborn. J Perinatol.
2024;44(1):119-24. DOI: https://www.nature.com/
articles/s41372-023-01850-x.
7. Marini G, Longhini J, Ambrosi E, Canzan F, Konradsen H,
Kabir ZN. Transitional Care Interventions in Improving Patient
and Caregiver Outcomes After Discharge: A Scoping Review.
InHealthcare. 2025;13(3)312-20. DOI: https://doi.org/10.3390
/healthcare13030312.
8. Ali S, Razzaq A, Shah SA, Ahmad Z. Intravenous Furosemide
in the Management of Transient Tachypnea of Newborn. Pak
Armed Forces Med J. 2023;73(3):666-9. DOI: https://doi.org/
10.51253/pafmj.v73i3.2792.
9. Kim MJ, Yoo J, Jung JA, Byun SY. The Effects of Inhaled
Albuterol in Transient Tachypnea of the Newborn. Allergy
Asthma Immunol Res. 2014;6(2):126-130. DOI: https://doi.org/
10.4168/aair.2014.6.2.126.
10. Armangil D, Yurdakok M, Korkmaz A, Yigit S, Tekinalp G.
Inhaled Beta-2 Agonist S albutamol for the Treatment of
Transient Tachypnea of the Newborn. J Pediatr.
2011;159(3):398-403. DOI: https://doi.org/10.1016/
j.jpeds.2011.02.028.
11. Alhassen Z, Vali P, Guglani L, Lakshminrusimha S, Ryan
RM. Recent advances in pathophysiology and management
of transient tachypnea of newborn. J Perinatol. 2021;41(1):6-
16. DOI: https://www.nature.com/articles/s41372-020-0757-
3.
12. Maneenil G, Janjindamai W, Dissaneevate S, Thatrimontrichai
A. Risk factors of transient tachypnea of the newborn
developing into pulmonary hypertension of the newborn: a
case-control study. Asian Biomedicine: Research, Reviews
and News. 2023;16(6):310. DOI: 0.2478/abm-2022-0034.
13. Baseer KA, Mohamed M, Abd-Elmawgood EA. Risk factors
of respiratory diseases among neonates in neonatal intensive
care unit of Qena University Hospital, Egypt. Ann Global
Health. 2020;86(1):22-7. DOI: 10.5334/aogh.2739.
14. Mallampalli RK, Acarregui MJ, Snyder JM. Differentiation
of the alveolar epithelium in the fetal lung. InLung growth
and development. 2024:119-162. DOI: 10.1201/
9781003574026-5.
15. de Abreu RA, de Almeida LL, da Rosa Filho RR, Angrimani
DD, Brito MM, Flores RB, et al. Canine pulmonary clearance
during feto-neonatal transition according to the type of delivery.
Theriogenol. 2024;224(5):156-62. DOI: https://doi.org/
10.1016/j.theriogenology.2024.05.022.
16. Beretta E, Romanò F, Sancini G, Grotberg JB, Nieman GF,
Miserocchi G. Pulmonary interstitial matrix and lung fluid
balance from normal to the acutely injured lung. Front physiol.
2021;12:781874. DOI: https://doi.org/10.3389/ fphys.2021.
781874.
17. Watson F, Austin P. Physiology of human fluid balance.
Anaesthesia & Intensive Care Medicine. 2021;22(10):644-
51. DOI: https://doi.org/10.1016/j.mpaic.2021.07.010.
18. Lucas R, Hadizamani Y, Enkhbaatar P, Csanyi G, Caldwell
RW, Hundsberger H, et al. Dichotomous role of tumor necrosis
factor in pulmonary barrier function and alveolar fluid
clearance. Front Physiol. 2022;12:793251. https://doi.org/
10.3389/fphys.2021.793251.
19. Yurdakök M, Yigit S, Korkmaz A, Tekinalp G. Inhaled
salbutamol therapy in transient tachypnea of the newborn.
Eur J Pediatr. 2018;167(11):1317–22.
20. Mohammadizadeh M, Ghazvini Z, Iranpour R. Inhaled
salbutamol for transient tachypnea of the newborn: a
randomized controlled trial. Int J Prev Med. 2022;3(12):
826–30. DOI: 10.5812/ijp.9633.
21. Dani C, Corsini I, Poggi C, Bertini G. Inhaled salbutamol in
transient tachypnea of the newborn. Early Hum Dev.
2022;88(1):51–4. DOI: https://doi.org/10.51642 /ppmj.
v34i01.541.
22. Sadeghnia A, Shajari A, Kashef S, Dalili H, Maleknejad S.
Efficacy of salbutamol in treatment of transient tachypnea of
the newborn: a systematic review and meta-analysis. Iran J
Pediatr. 2019;25(5):e367. DOI: DOI: 10.21608/ijma.2020.
21436.1064.
23. Malakian A, Bashar FR. Effect of nebulized salbutamol on
clinical course of transient tachypnea of the newborn. J Res
Med Sci. 2019;21:56. DOI: https://doi.org/10.1016/j.
jcma.2018.01.015.
24. Jain L, Eaton DC. Beta-adrenergic agonists and lung fluid
absorption: evolving therapy for neonatal respiratory disorders.
Clin Perinatol. 2018;35(1):185–202. DOI: https://link.
springer.com/chapter/10.1007/978-981-33-6009-9_4.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0
